Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 8, 2017

Rgenix begins Phase Ia/b study of RGX-104 to treat cancer

US-based clinical stage bio-pharmaceutical company Rgenix has begun its Phase Ia/b study of RGX-104 to treat advanced solid malignancies and lymphoma.

US-based clinical stage bio-pharmaceutical company Rgenix has begun its Phase Ia/b study of RGX-104 to treat advanced solid malignancies and lymphoma.

RGX-104 is an orally administered, bioavailable, small molecule immunotherapy developed to target the liver X receptors (LXR) to activate expression of the ApoE protein.

It affects both myeloid-derived suppressor cells (MDSCs), as well as tumour blood vessels. MDSCs are known to inhibit T-cells and other immune system cells from attacking tumours.

The study will be divided into an initial dose-escalation stage, which will determine the pharmacokinetic, pharmacodynamic, biomarker and safety of an optimal biological dose RGX-104 while treating patients with advanced solid malignancies and lymphoma.

"RGX-104 represents the first LXR-ApoE targeting drug in clinical development for cancer."

The expansion stage of the study will assess the preliminary efficacy of RGX-104, while examining patients with at least four types of cancers.

Rgenix co-founder and CEO Masoud Tavazoie said: “RGX-104 represents the first LXR-ApoE targeting drug in clinical development for cancer.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“Because of its ability to inhibit tumour growth and metastasis as a single agent in drug-resistant cancer types via a novel mechanism, RGX-104 has the potential to transform the treatment landscape for several common cancer types, addressing urgent unmet needs in oncology.”

RGX-104 has demonstrated efficacy in reversing the immunosuppressive and pro-angiogenic effects of cancers by activating ApoE expression in cancer and highly specific circulating immune cells, which finally leads to killing these cells and blood vessels within the tumour microenvironment.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU